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ReOBJECTIVES This study compared clinical outcomes and revascularization strategies among patients presenting with
low ejection fraction, low-gradient (LEF-LG) severe aortic stenosis (AS) according to the assigned treatment modality.
BACKGROUND The optimal treatment modality for patients with LEF-LG severe AS and concomitant coronary artery
disease (CAD) requiring revascularization is unknown.
METHODS Of 1,551 patients, 204 with LEF-LG severe AS (aortic valve area <1.0 cm2, ejection fraction <50%, and mean
gradient <40 mm Hg) were allocated to medical therapy (MT) (n ¼ 44), surgical aortic valve replacement (SAVR)
(n ¼ 52), or transcatheter aortic valve replacement (TAVR) (n ¼ 108). CAD complexity was assessed using the SYNTAX
score (SS) in 187 of 204 patients (92%). The primary endpoint was mortality at 1 year.
RESULTS LEF-LG severe AS patients undergoing SAVR were more likely to undergo complete revascularization
(17 of 52, 35%) compared with TAVR (8 of 108, 8%) and MT (0 of 44, 0%) patients (p < 0.001). Compared with MT,
both SAVR (adjusted hazard ratio [adj HR]: 0.16; 95% conﬁdence interval [CI]: 0.07 to 0.38; p < 0.001) and TAVR
(adj HR: 0.30; 95% CI: 0.18 to 0.52; p < 0.001) improved survival at 1 year. In TAVR and SAVR patients, CAD severity
was associated with higher rates of cardiovascular death (no CAD: 12.2% vs. low SS [0 to 22], 15.3% vs. high SS [>22],
31.5%; p ¼ 0.037) at 1 year. Compared with no CAD/complete revascularization, TAVR and SAVR patients undergoing
incomplete revascularization had signiﬁcantly higher 1-year cardiovascular death rates (adj HR: 2.80; 95% CI: 1.07 to
7.36; p ¼ 0.037).
CONCLUSIONS Among LEF-LG severe AS patients, SAVR and TAVR improved survival compared with MT. CAD severity
was associated with worse outcomes and incomplete revascularization predicted 1-year cardiovascular mortality among
TAVRandSAVRpatients. (J AmColl Cardiol Intv 2015;8:704–17)©2015by theAmericanCollege of Cardiology Foundation.m the *Department of Cardiology, Bern University Hospital, Bern, Switzerland; yDepartment of Cardiology, Stadtspital Triemli,
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AB BR E V I A T I O N S
AND ACRONYM S
adj HR = adjusted hazard ratio
AS = aortic stenosis
AVA = aortic valve area
CABG = coronary artery
bypass grafting
CAD = coronary artery disease
CI = conﬁdence interval
LEF-LG = low ejection
fraction, low gradient
LV = left ventricular
LVEF = left ventricular
ejection fraction
MT = medical therapy
PCI = percutaneous
coronary intervention
SAVR = surgical aortic
valve replacement
SS = SYNTAX score
TAVR = transcatheter aortic
valve replacement
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705P atients presenting with low ejection fractionheart failure and severe aortic stenosis (AS)typically exhibit a low mean gradient on he-
modynamic evaluation despite the presence of a tight
aortic valve oriﬁce (1–5). Patients with this condition,
low ejection fraction, low-gradient (LEF-LG) severe
AS, present a management challenge because previ-
ous studies have shown LEF-LG severe AS patients
undergoing conventional surgical aortic valve
replacement (SAVR) to have a high perioperative mor-
tality rate (range 6% to 33%), particularly in the
absence of ﬂow reserve, but an abysmal outcome
when managed conservatively (2–4,6–13).
Transcatheter aortic valve replacement (TAVR) is a
novel, less invasive alternative for the treatment of
high-risk or inoperable patients presenting with se-
vere AS (14,15). Because most patients presenting
with low ejection fraction heart failure and severe AS
are deemed high risk, TAVR may be an attractive
option for these patients (5,16,17). A recent post-hoc
analysis of the PARTNER (Placement of Aortic
Transcatheter Valves) trial underscored the dismal
outcome of patients with LEF-LG severe AS assigned
to conservative management but also revealed for the
ﬁrst time that LEF-LG severe AS patients undergoing
TAVR and SAVR had similar mortality rates at 2 years
(18). However, this study was limited by the fact that
the PARTNER trial systematically excluded all pa-
tients with coronary artery disease (CAD) requiring
revascularization and a left ventricular ejection frac-
tion (LVEF) <20% and no echocardiographic follow-
up was reported (18). However, LEF-LG severe AS
patients undergoing conventional aortic valve
replacement in the “real world” typically have a high
prevalence of concomitant CAD (66% to 69%) (4,6).
Furthermore, little is known about revascularization
strategies in LEF-LG severe AS patients, particularly
among those undergoing TAVR. The primary aim of
the present study was to describe “real-world” clin-
ical outcomes of LEF-LG severe AS patients according
to the assigned treatment modality (i.e., medical
therapy [MT], SAVR, or TAVR). The secondary aim
was to quantify CAD severity among LEF-LG severe
AS patients using the SYNTAX score (SS) (19) and to
describe the revascularization strategies and the
completeness of revascularization among patients
with left ventricular (LV) systolic dysfunction andLifesciences; and is a consultant for Medtronic. Dr. Buellesfeld is a consulta
Vascular. Dr. Khattab is a proctor for Medtronic and Edwards Lifesciences.
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assigned treatment modality.METHODS
PATIENT POPULATION. The present study
included patients meeting inclusion criteria
who underwent TAVR, SAVR, or MT between
January 2005 and December 2012 at Bern
University Hospital, Bern, Switzerland. Inclu-
sion criteria were as follows: 1) LVEF <50%; 2)
mean gradient#40mmHg; 3) aortic valve area
(AVA)<1 cm2; 4) native aortic valve; and 5) age
70 years or older. Exclusion criteria consisted
of patients undergoing a concomitant valve
procedure (e.g., mitral valve replacement or
repair) or aortic surgery (e.g., aortic root
enlargement, Bentall procedure), previous
valve replacement or repair, redo sternotomy
in SAVR patients, patients presenting with
unstable acute coronary syndromes, and pa-
tients undergoing emergency procedures. Pa-
tients undergoing concomitant revascularization
procedures (i.e., percutaneous coronary intervention
[PCI] or coronary artery bypass grafting [CABG]) were
included.
MULTIDISCIPLINARY EVALUATION FOR HIGH-RISK
PATIENTS ANDASSIGNMENT TO TREATMENT MODALITY.
Since the beginning of the TAVR program at our
institution in August 2007, all patients with severe AS
at increased surgical risk underwent a multidisci-
plinary assessment according to a standardized pro-
tocol during a short hospitalization, as previously
described (20). Between January 2005 and July 2007,
the only treatment options for patients presenting
with symptomatic severe AS at our institution
were MT and conventional SAVR. The evaluation in-
cluded both a noninvasive (transthoracic and trans-
esophageal echocardiography, computed tomography
angiography) and invasive (left and right heart cath-
eterization, aortography) assessment. Risk algorithms
(logistic EuroSCORE and Society of Thoracic Surgeons
score) were used as an aid for patient selection and
treatment allocation. Since August 2007, the selection
of the most appropriate treatment strategy for high-
risk patients was based on a consensus decision bynt for Medtronic, Edwards Lifesciences, and Abbott
All other authors have reported that they have no
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706the Heart Team. Treatment allocation was based on
anatomic and technical considerations, estimated
periprocedural risk, and patient preference.
The present analysis included all patients with
LEF-LG severe AS meeting inclusion criteria under-
going SAVR between January 2005 and December
2012 and those assigned to MT or TAVR between
August 2007 and December 2012. MT comprised
treatment of comorbidities according to best clinical
practice. In patients with severe CAD and symptom-
atic angina, PCI was performed as indicated. Balloon
aortic valvuloplasty was not offered as part of the
medical treatment strategy or as a bridge to SAVR. In
some cases, treatment allocation was reconsidered
and discussed with the Heart Team. Consequently,
some patients originally assigned to undergo MT were
crossed over to either TAVR or SAVR at a later stage.
SAVR was performed as previously described in
detail (20). TAVR was performed with either the
CoreValve (Medtronic, Minneapolis, Minnesota) or
the SAPIEN valve (Edwards Lifesciences, Irvine, Cal-
ifornia) via transfemoral, transapical, or a trans-
subclavian access using standard techniques (20).
Coronary revascularization was performed if indi-
cated on the basis of coronary angiography ﬁndings. In
patients undergoing SAVR, revascularization was
performed using arterial or venous conduits. In pa-
tients undergoing TAVR, revascularization by PCI was
performed in proximal coronary segments with a
diameter stenosis $70% either as a staged or concom-
itant procedure.
ANGIOGRAPHIC ANALYSIS. All coronary angio-
graphic analyses for calculation of the baseline SS (all
patients with available angiograms; n ¼ 187 of 204
[92%]) and residual SS (MT and TAVR patients only;
n ¼ 145 of 204 [71%]) were performed at the Core
Angiographic Laboratory of the Department of Cardi-
ology at Bern University Hospital, Bern, Switzerland,
as previously described (21). Brieﬂy, all available
baseline coronary angiograms of patients were
reviewed by 2 experienced invasive cardiologists
trained in the assessment of SS and blinded to clinical
outcomes (22). For patients with CAD, baseline SS
(i.e., SS before any PCI) was calculated by the
consensus of the 2 readers using the SS algorithm
(available at www.syntaxscore.com) (19). In case of
disagreement, the opinion of a third reviewer was
obtained, and a ﬁnal consensus decision was reached.
The SS of patients without CAD was deemed to be 0.
For patients with a previous CABG, the CABG SS was
used (23). For MT and TAVR patients undergoing PCI,
the extent and complexity of untreated CAD were
determined by assessing the residual SS (24).Complete revascularization was deﬁned as treatment
of any lesion with a stenosis diameter more than 50%
in vessels $1.5 mm as estimated on the diagnostic
angiogram as previously described (25).
DATA COLLECTION. Patients were included in the
present registry at the time of SAVR or TAVR; for
patients receiving MT, the date of hospitalization for
multimodality evaluation was used as the inclusion
date. Follow-up was performed by means of stan-
dardized telephone interviews or clinic visits. Medi-
cal records, discharge summaries, and documentation
of hospitalization were systematically collected from
referring hospitals and general practitioners. Patient
and procedure characteristics as well as follow-up
data were entered into a dedicated database held at
the Clinical Trials Unit in Bern, Switzerland.
DEFINITIONS. Deﬁnitions used in the present anal-
ysis have been previously reported (20). All events
were adjudicated by a clinical events committee
comprising interventional cardiologists and cardiac
surgeons. Cardiovascular death was deﬁned as death
secondary to a proximate cardiac cause and was
assumed when the cause of death was unknown.
Myocardial infarction was deﬁned as an increase in at
least 1 value of a cardiac biomarker above the 99th
percentile of the upper reference limit more than
72 h after intervention in combination with evidence
of myocardial ischemia determined by one of the
following: electrocardiographic changes indicative of
new ischemia, new pathological Q waves in at least
2 contiguous leads, or imaging evidence of a new loss
of viable myocardium or new wall motion abnormal-
ity. Major stroke was documented in case of a
rapid onset of focal or global neurological deﬁcit
of $24-h duration, requiring therapeutic interven-
tion, or documentation of a new intracranial defect
using magnetic resonance imaging or computed to-
mography. Transient ischemic attack as determined
as a neurological deﬁcit with complete remission
within 24 h of onset. Major adverse cerebro-
cardiovascular events comprised all-cause mortality,
myocardial infarction, and major stroke.
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD if their distribution is
approximately normal and as median/range other-
wise. The means were compared using analysis of
variance, and the differences in medians were eval-
uated with the Mann-Whitney or Kruskal-Wallis
test. Categorical data are expressed as frequency
(percent) and were compared using the chi-square
and Fisher exact tests. Survival was estimated using
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707the Kaplan-Meier method, and differences in esti-
mates were compared by means of the log-rank test.
All time-to-event analyses were based on the initial
treatment allocation, in analogy to the intention-
to-treat principle unless otherwise speciﬁed. The
at-risk time span was derived from the date of inter-
vention on one side and the last available date of a pa-
tient on the other side, determined either by the date
of death or the last follow-up or information coming
from referring hospitals and practitioners. Univariate
and multivariate Cox proportional hazard models
were used to derive crude and adjusted survival esti-
mates and to assess the association of baseline charac-
teristics with clinical outcomes. Adjusted hazard ratios
(adj HRs) and 95% conﬁdence intervals (CIs) were de-
rived from Cox regression analyses, adjusting for the
following baseline variables: hypercholesterolemia,
peripheral vascular disease, previous cardiac surgery,
atrial ﬁbrillation, and the logistic EuroSCORE, after
multiple imputations of missing values using chained
equations (20 datasets produced). Life expectancy
after conversion to either SAVR or TAVRwas predicted
using Poisson regression. All p values and 95% CIs
are 2-sided, and all analyses were performed using
STATA version 13 (StataCorp, College Station, Texas).
RESULTS
BASELINE CHARACTERISTICS. Patient characteris-
tics are shown in Table 1, and patient ﬂow is shown in
Figure 1. A total of 1,551 patients were screened for
inclusion in the present study during the inclusion
period: 606 consecutive patients undergoing TAVR
(August 2007 to December 2012), 835 patients
70 years of age and older without previous sternot-
omy undergoing SAVR (with or without CABG but
without concomitant valvular intervention; January
2005 to December 2012), and 110 patients assigned to
MT (August 2007 to December 2012). Of these, 204
patients with LEF-LG severe AS met inclusion criteria
for the present analysis (108 TAVR, 52 SAVR, and
44 MT). The reasons for allocation of LEF-LG severe
AS patients to MT were comorbidities with a poor
prognosis (38.6%), excessive peri-interventional risk
(13.6%), anatomic reasons (11.4%), and patient pref-
erence (36.4%). Patients allocated to SAVR were sig-
niﬁcantly younger and were at lower risk compared
with patients allocated to TAVR and MT. MT patients
had higher rates of renal failure, atrial ﬁbrillation,
previous CABG, and a trend toward more complex
CAD as assessed using the SS compared with SAVR
and TAVR patients. TAVR patients had higher rates of
previous PCI and were more symptomatic compared
with MT and SAVR patients.ECHOCARDIOGRAPHIC AND INVASIVE HEMODYNAMIC
CHARACTERISTICS. Echocardiographic and invasive
hemodynamic characteristics at baseline are shown
in Tables 2 and 3, respectively. Compared with
SAVR patients, both MT and TAVR patients had
signiﬁcantly worse LV and right ventricular systolic
function, a higher prevalence of moderate to severe
mitral and tricuspid regurgitation, lower invasive
mean gradients, lower stroke volumes and cardiac
outputs, and higher pulmonary artery systolic
pressures measured both echocardiographically and
invasively. There were no signiﬁcant differences
in other hemodynamic parameters. Dobutamine
stress echocardiography was performed in 48 of 204
patients (24%). Flow reserve was present in 40%,
100%, and 73% of MT, SAVR, and TAVR patients un-
dergoing dobutamine stress echocardiography,
respectively.
PROCEDURAL CHARACTERISTICS. Procedural char-
acteristics are shown in Table 4. Three LEF-LG severe
AS patients originally allocated to MT were crossed
over to TAVR and 1 transapical TAVR patient was
emergently crossed over to SAVR and subsequently
died. TAVR was performed using conscious sedation
in the majority of patients (60%). The Medtronic
CoreValve was used in most TAVR patients. SAVR
patients received either a stented (n ¼ 48) or stentless
(n ¼ 4) bioprostheses. The most frequently implanted
stented bioprosthesis was the Perimount Magna
Ease bioprosthesis (n ¼ 38) (Edwards Lifesciences),
whereas the most frequently implanted stentless
bioprosthesis was the Sorin Freedom SOLO (n ¼ 3)
(Sorin Group, Milan, Italy). Patients undergoing SAVR
had a signiﬁcantly longer length of hospital stay
compared with MT and TAVR patients (MT vs. SAVR
vs. TAVR: 4.9  5.6 days vs. 11.9  4.6 days vs. 8.5 
4.1 days; p < 0.001). Revascularization was performed
in 69% of patients selected for SAVR by means of
CABG, 36% of patients undergoing TAVR by means of
either staged (21%) or concomitant (15%) PCI, and 16%
of MT patients by PCI. Complete revascularization
was achieved in 17 of 52 SAVR patients (35%), 8 of 108
TAVR patients (8%), and 0 of 44 of MT patients (0%)
(p < 0.001). SAVR patients were more likely to un-
dergo additional concomitant interventions, with
occlusion of the left atrial appendage being the most
frequent structural intervention performed (Table 4).
CLINICAL OUTCOMES ACCORDING TO TREATMENT
MODALITY. All comparisons among the 3 treatment
arms are descriptive. One-year follow-up was com-
plete for 100% patients allocated to MT, 99% of pa-
tients assigned to TAVR (1 TA patient withdrew
consent after 113 days), and 92% of patients assigned
TABLE 1 Baseline Characteristics
MT
(n ¼ 44)
SAVR
(n ¼ 52)
TAVR
(n ¼ 108) p Value
Age, yrs 82.7  4.7 78.4  4.1 82.5  4.4 <0.001
Female 18 (41) 19 (37) 45 (42) 0.82
Height, cm 166.9  8.2 167.1  8.9 165.3  8.0 0.35
Weight, kg 68.2  11.2 74.0  15.3 69.6  14.4 0.09
Body mass index, kg/m2 24.6  3.2 26.4  4.6 25.4  4.8 0.13
Body surface area, m2 1.8  0.2 1.8  0.2 1.8  0.2 0.15
Cardiac risk factors
Diabetes mellitus 13 (30) 17 (33) 35 (32) 0.93
Hypercholesterolemia 25 (57) 32 (62) 72 (67) 0.50
Hypertension 31 (70) 43 (83) 87 (81) 0.29
Current smoker 5 (11%) 23 (44%) 12 (11%) <0.001
Medical history
Previous stroke 9 (20) 7 (13) 9 (8) 0.11
Peripheral vascular disease 11 (25) 6 (12) 29 (27) 0.09
Chronic obstructive pulmonary disease 10 (23) 7 (13) 17 (16) 0.45
Renal failure (GFR <50 ml/min/1.73 m2) 31 (74) 20 (38) 36 (33) <0.001
Previous permanent pacemaker 5 (11) 9 (17) 13 (12) 0.60
Coronary artery disease
SYNTAX score* 22.3  19.3 14.0  14.1 16.1  15.5 0.06
Coronary artery disease 32 (73) 40 (77) 80 (74) 0.89
Previous MI 15 (34) 13 (25) 27 (25) 0.49
Previous CABG 15 (34) 0 (0) 27 (25) <0.001
Previous PCI 9 (20) 4 (8) 42 (39) <0.001
Baseline cardiac rhythm
Atrial ﬁbrillation 22 (50) 17 (33) 30 (28) 0.04
Symptoms
NYHA functional class III/IV 29 (66) 35 (67) 85 (82) 0.05
CCS angina status III/IV 7 (16) 13 (25) 16 (15) 0.27
Risk assessment
Logistic EuroSCORE, % 41.2  16.0 18.7  13.0 34.5  15.3 <0.001
STS score, % 11.2  7.3 4.9  2.9 7.9  4.9 <0.001
STS score, % 9.8 (5.9–15.8) 4.2 (3.2–5.5) 6.6 (4.6–9.9) <0.001
Medications
Aspirin 21 (48) 40 (77) 72 (67) 0.01
Clopidogrel 8 (18) 2 (4) 29 (27) 0.00
Oral anticoagulation 18 (41) 11 (21) 34 (31) 0.11
Values are mean  SD with p values from analyses of variance or n (%) with p values from chi-square tests. STS
score was left-skewed, and therefore also median (25% to 75% interquartile range) with Kruskal-Wallis and
Mann-Whitney U tests is reported. *Sample sizes for SYNTAX score: 33, 48, 106; renal failure, n ¼ 2 missing for
medical therapy; chronic obstructive pulmonary disease, n ¼ 1 missing for transcatheter aortic valve replacement;
atrial ﬁbrillation; n ¼ 2 missing for transcatheter aortic valve replacement.
CABG ¼ coronary artery bypass grafting; CCS ¼ Canadian Cardiovascular Society; GFR ¼ glomerular ﬁltration
rate; MI¼myocardial infarction; MT ¼medical therapy; NYHA¼ New York Heart Association; PCI¼ percutaneous
coronary intervention; SAVR ¼ surgical aortic valve replacement; STS ¼ Society of Thoracic Surgeons;
TAVR ¼ transcatheter aortic valve replacement.
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708to SAVR. The median duration of clinical follow-up
was 365 days (interquartile range: 240 to 365 days,
i.e., longer follow-ups censored at 1 year). Unadjusted
and adjusted event rates at 30 days and 1 year are
provided in Tables 5 and 6, respectively. Compared
with MT patients, patients undergoing both TAVR
and SAVR had similar 30-day survival rates after
adjustment for baseline comorbidities (MT vs. SAVR,
adj HR: 0.64; 95% CI: 0.16 to 2.61; p ¼ 0.54; MT vs.
TAVR, adj HR: 0.36; 95% CI: 0.13 to 1.04; p ¼ 0.058).No signiﬁcant differences in all-cause mortality were
observed between SAVR and TAVR patients at 30 days
(adj HR: 0.69; 95% CI: 0.14 to 3.35; p ¼ 0.65). Patients
assigned to TAVR had signiﬁcantly higher rates of
bleeding and vascular complications and permanent
pacemaker implantation, and patients assigned to
SAVR had signiﬁcantly higher rates of acute renal
failure. Two SAVR patients required a periprocedural
redo sternotomy for management of pericardial
tamponade.
Survival curves showing all-cause death and car-
diovascular death at 1 year according to treatment
modality are shown in Figure 2. At 1 year, both SAVR
and TAVR signiﬁcantly improved survival compared
with MT among patients presenting with LEF-LG se-
vere AS (MT vs. SAVR, unadjusted HR: 0.16; 95% CI:
0.07 to 0.38; p < 0.001; MT vs. TAVR, HR: 0.30; 95%
CI: 0.18 to 0.52; p < 0.001). Mortality was predomi-
nantly driven by cardiovascular death in all groups.
After adjustment for univariate predictors of 1-year
mortality (peripheral vascular disease, atrial ﬁbrilla-
tion, and logistic EuroSCORE), both SAVR and TAVR
improved survival compared with MT (MT vs. SAVR,
adj HR: 0.37; 95% CI: 0.15 to 0.93; p ¼ 0.034; MT vs.
TAV, adj HR: 0.43; 95% CI: 0.24 to 0.79; p ¼ 0.006)
(Table 6). No signiﬁcant differences in adjusted
overall mortality (adj HR: 1.28; 95% CI: 0.51 to 3.22;
p ¼ 0.60) or cardiovascular death (adj HR: 1.49; 95%
CI: 0.52 to 4.23; p ¼ 0.46) rates were observed in pa-
tients undergoing SAVR and TAVR at 1 year.
CLINICAL OUTCOMES ACCORDING TO BASELINE
CAD SEVERITY AND COMPLETENESS OF REVASCU-
LARIZATION (SAVR AND TAVR PATIENTS ONLY).
In total, 187 of 204 patients (91.7%) had a baseline
angiogram available for evaluation, and CAD was
conﬁrmed to be present in 138 of 187 LEF-LG severe
AS patients (73.8%). Survival curves showing all-
cause mortality and cardiovascular death according
to baseline SS in patients undergoing TAVR and SAVR
only (i.e., MT patients excluded) at 1 year are shown
in Figure 3. Compared with no CAD, LEF-LG severe AS
patients with a high SS (>22) had signiﬁcantly higher
rates of cardiovascular death (12.2% vs. 31.5%; adj HR:
3.29; 95% CI: 1.08 to 10.05; p ¼ 0.037) and a trend
toward higher rates of overall mortality (16.8% vs.
33.7%; adj HR: 2.59; 95% CI: 0.95 to 7.03; p ¼ 0.062) at
1 year. Compared with no CAD, no signiﬁcant differ-
ences in cardiovascular death (p ¼ 0.86) or all-cause
death (p ¼ 0.98) were observed among patients with
a low to intermediate SS (0 to 22) at 1 year (Online
Tables 1 to 3).
Survival curves showing all-cause death and car-
diovascular death rates according to completeness of
FIGURE 1 Patient Flow
The 835 SAVR patients were all 70 years or older without a previous sternotomy undergoing SAVR (with or without coronary artery bypass grafting) without a
concomitant valvular intervention between January 2005 and December 2012. LVEF ¼ left ventricular ejection fraction; MT ¼ medical therapy; SAVR ¼ surgical aortic
valve replacement; TAVR ¼ transcatheter aortic valve replacement.
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709revascularization by either CABG or PCI in patients
undergoing SAVR and TAVR only (i.e., MT patients
were excluded) are shown in Figure 4. Compared with
no CAD/complete revascularization, LEF-LG severe
AS patients undergoing incomplete revascularization
had signiﬁcantly higher rates of overall (13.6% vs.
29.2%; HR: 2.30; 95% CI: 1.07 to 4.92; p ¼ 0.032) and
cardiac mortality (9.1% vs. 27.0%; HR: 3.15; 95% CI:
1.28 to 7.74; p ¼ 0.012) at 1 year. After adjustment,
incomplete revascularization remained an indepen-
dent predictor of cardiovascular mortality (adj HR:
2.80; 95% CI: 1.07 to 7.36; p ¼ 0.037) at 1 year (Online
Tables 4 and 5).
ECHOCARDIOGRAPHIC OUTCOMES. Echocardiographic
characteristics are shown in Table 7. No signiﬁcant
differences in indexed AVAs were observed between
TAVR and SAVR groups at discharge (SAVR vs. TAVR:
1.03  0.22 vs. 1.05  0.37 cm2$m2) or 1 year (0.94 
0.27 vs. 1.00  0.27 cm2$m2; p ¼ 0.49) follow-up.
However, compared with SAVR, TAVR patients had
signiﬁcantly lower mean gradients at both discharge
(9.49  3.40 vs. 7.20  2.94 mm Hg; p ¼ 0.001) and
1-year follow-up (11.52  3.58 vs. 8.06  2.92 mm Hg;
p < 0.001). No signiﬁcant differences in rates of
patient prosthetic mismatch (indexed AVA #0.85
cm2$m2) were observed between the SAVR and
TAVR groups at either discharge (p ¼ 0.32) or 1-year(p ¼ 0.10) follow-up. Compared with SAVR patients,
those undergoing TAVR had a signiﬁcantly higher
incidence of moderate to severe paravalvular aortic
regurgitation at both discharge (1% vs. 17%; p < 0.001)
and 1 year (0% vs. 15%; p ¼ 0.001) follow-up. LVEF
recovery up to 1 year in LEF-LG severe AS patients
undergoing TAVR and SAVR is shown in Figure 5.
Compared with SAVR patients, TAVR patients exhibi-
ted better early improvement in LVEF on discharge
echocardiography (DLVEF in SAVR vs. TAVR: 0.2 
15.3% vs. 4.7  10.3%; p ¼ 0.041). However, both
SAVR and TAVR patients had similar LVEF impro-
vement at 1-year follow-up (DLVEF in SAVR vs.
TAVR: 7.8  16.2% vs. 10.0  12.2%; p ¼ 0.54).DISCUSSION
The main ﬁndings of the present study were as fol-
lows: First, both TAVR and SAVR improved survival
compared with MT in LEF-LG severe AS patients at
1-year follow-up. No signiﬁcant differences in mor-
tality rates were observed between TAVR and SAVR
patients at either 30 days or 1 year even though SAVR
patients were at considerably lower risk and had a
more favorable hemodynamic proﬁle at baseline
compared with TAVR and MT patients. Second,
LEF-LG severe AS was associated with a high
TABLE 2 Echocardiographic Characteristics
MT
(n ¼ 44)
SAVR
(n ¼ 52)
TAVR
(n ¼ 108) p Value
Aortic stenosis severity
Aortic valve area, cm2 0.70  0.22 0.73  0.23 0.74  0.21 0.56
Indexed aortic valve area, cm2$m2 0.40  0.13 0.41  0.12 0.42  0.12 0.51
Aortic maximal velocity, cm/s 2.97  0.48 3.32  0.60 3.24  0.61 0.05
Mean gradient, mm Hg 25.25  9.37 29.26  9.54 28.57  10.29 0.11
Peak gradient, mm Hg 40.66  14.40 48.34  15.89 46.55  15.98 0.05
LV geometry and 2D measurements
Interventricular septum in diastole, mm 12.75  2.82 16.24  9.62 12.86  3.15 0.014
Posterior wall thickness in diastole, mm 12.76  5.86 11.40  2.46 12.56  7.00 0.60
LV end-systolic diameter, mm 46.23  10.90 43.10  8.01 43.93  10.81 0.46
LV end-diastolic diameter, mm 54.93  9.64 54.15  10.02 55.22  10.56 0.86
Relative wall thickness 0.51  0.32 0.48  0.32 0.51  0.39 0.94
LV mass index, g/m2 173.52  60.22 164.09  46.25 159.77  36.20 0.38
Geometry 0.87
Normal 1 (3) 2 (11) 3 (5) 0.54
Concentric hypertrophy 12 (41) 7 (39) 25 (45) 0.90
Eccentric hypertrophy 12 (41) 8 (44) 24 (43) 0.98
Concentric remodeling 4 (14) 1 (6) 4 (7) 0.51
LV systolic function
LV ejection fraction, % 29.64  9.33 38.90  11.95 34.52  11.38 <0.001
LV ejection fraction #30% 35 (79.5) 16 (30.8) 59 (54.6) <0.001
LV ejection fraction #20% 13 (29.5) 6 (11.5) 19 (17.6) 0.07
LV diastolic function
E/A ratio 2.09  0.86 1.47  0.82 1.93  1.08 0.21
Deceleration time, ms 147.30  38.46 173.95  60.95 173.35  65.79 0.46
Isovolumic relaxation time, ms 77.33  17.86 92.50  23.54 80.73  34.38 0.62
Left atrial diameter, mm 50.58  9.45 45.43  8.42 49.09  6.01 0.029
RV systolic function
TAPSE, mm 12.74  5.29 16.50  4.70 14.33  4.52 0.07
DTI S0, cm/s 8.54  2.32 12.23  2.79 9.53  2.97 <0.001
Associated valvular abnormality
Aortic regurgitation 0.32
None 15 (37) 16 (36) 27 (27)
Mild 24 (59) 26 (59) 63 (64)
Moderate 2 (5) 1 (2) 9 (9)
Severe 0 (0) 1 (2) 0 (0)
Mitral regurgitation 0.036
None 4 (10) 5 (10) 2 (2)
Mild 16 (39) 30 (60) 49 (45)
Moderate 19 (46) 15 (30) 54 (50)
Severe 2 (5) 0 (0) 3 (3)
Tricuspid regurgitation 0.03
None 4 (10) 5 (11) 10 (11)
Mild 21 (53) 35 (76) 51 (55)
Moderate 9 (23) 6 (13) 27 (29)
Severe 6 (15) 0 (0) 5 (5)
Right-sided hemodynamics
RV/RA gradient, mm Hg 43.04  16.27 35.89  11.11 41.94  11.98 0.043
PA systolic pressure, mm Hg 52.88  17.70 45.49  11.93 52.03  13.87 0.049
Vales are mean  SD with p values from analyses of variance or n (%) with p values from chi-square tests.
2D ¼ 2-dimensional; DTI S0 ¼ pulsed Doppler peak velocity at the annulus; LV ¼ left ventricular; PA ¼ pulmonary artery; RA ¼ right atrial; RV ¼ right ventricular;
TAPSE ¼ tricuspid annular plane systolic excursion; other abbreviations as in Table 1.
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TABLE 3 Invasive Hemodynamic Characteristics
MT
(n ¼ 44)
SAVR
(n ¼ 52)
TAVR
(n ¼ 108) p Value
Aortic stenosis severity
Aortic valve area, cm2 0.60  0.21 0.59  0.20 0.68  0.30 0.16
Indexed aortic valve area, cm2$m2 0.34  0.10 0.32  0.12 0.38  0.18 0.20
Peak-to-peak gradient, mm Hg 31.60  16.39 32.06  20.09 31.42  21.37 0.99
Mean gradient, mm Hg 23.50  10.67 29.81  7.29 25.96  8.55 0.013
Systemic vascular load
Systolic arterial pressure, mm Hg 116.97  23.50 129.00  23.61 125.76  25.48 0.12
Diastolic arterial pressure, mm Hg 64.68  13.77 68.33  15.46 66.59  14.50 0.59
Mean arterial pressure, mm Hg 87.16  16.50 92.11  16.00 90.75  16.47 0.44
Systemic vascular resistance, mm Hg$min$l1 2,036.07  702.33 1,888.29  493.85 2,105.45  726.18 0.34
Systemic arterial compliance, ml$mm Hg1 0.46  0.24 0.48  0.16 0.46  0.25 0.95
LV global afterload
Valvuloarterial impedance, mm Hg$ml1$m2 6.94  2.37 6.75  2.16 6.99  2.51 0.91
LV systolic function
Angiographic ejection fraction, % 29.17  9.08 36.08  8.62 32.43  8.50 0.007
LV end-systolic pressure, mm Hg 149.21  27.83 162.00  26.00 156.42  24.87 0.15
LV end-diastolic pressure, mm Hg 21.93  7.86 24.35  24.45 21.94  7.70 0.66
Stroke volume, ml 38.67  12.31 49.22  20.20 43.50  14.05 0.029
Stroke volume index, ml/m2 21.79  5.66 26.03  9.77 24.47  7.31 0.09
Cardiac output, l/min 3.11  0.69 3.77  1.17 3.38  1.01 0.023
Cardiac index, l/(min$m2) 1.75  0.30 2.05  0.60 1.90  0.50 0.049
Heart rate (beats/min) 83.39  14.60 82.64  16.96 79.94  16.36 0.51
Right-sided hemodynamics
PA systolic pressure, mm Hg 59.32  15.92 50.63  16.15 58.01  14.51 0.031
Mean PA pressure, mm Hg 38.32  10.11 33.71  11.54 38.41  10.00 0.07
Pulmonary hypertension 27 (87) 26 (74) 71 (87) 0.22
Vales are mean  SD with p values from analyses of variance or n (%) with p values from chi-square tests.
Abbreviations as in Tables 1 and 2.
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moderate complexity in the present analysis. We
found that a higher degree of CAD complexity (SS
>22) was an independent predictor of cardiovascular
death at 1 year in LEF-LG severe AS patients under-
going TAVR and SAVR. Therefore, revascularization
strategies are an important consideration in the
overall management of patients presenting with LEF-
LG severe AS. LEF-LG severe AS patients undergoing
SAVR were almost twice as likely to undergo revas-
cularization and more than 4 times as likely to be
completely revascularized compared with LEF-LG
severe AS patients undergoing TAVR despite having
a similar degree of CAD complexity at baseline.
Furthermore, incomplete revascularization was an
independent predictor of 1-year cardiovascular mor-
tality in LEF-LG severe AS patients with CAD under-
going TAVR and SAVR. Therefore, LEF-LG severe AS
patients with concomitant CAD of high complexity
should be considered for SAVR and CABG if the risk
proﬁle permits. Complete revascularization should be
considered in inoperable LEF-LG severe AS patients
with concomitant CAD of high complexity. Third,LVEF improved to a similar extent in both SAVR and
TAVR patients at 1-year follow-up. However, the
timing of LVEF improvement differed in both groups,
with TAVR patients experiencing an early improve-
ment in LVEF before discharge and those undergoing
SAVR experiencing most LVEF improvement after
discharge. Finally, we observed patients undergoing
TAVR to have signiﬁcantly lower post-procedural
mean gradients compared with SAVR patients,
although no differences in post-procedural AVAs
were observed in the TAVR and SAVR groups.
LOW EJECTION FRACTION, LOW-GRADIENT SEVERE
AS AND SAVR. The ﬁrst description of LEF-LG severe
AS and its association with a high perioperative
mortality during SAVR was made by Carabello et al.
(1) in 1980. Several subsequent reports conﬁrmed this
association (2–4,6–9,12,13). In a pivotal study in 1995,
deFilippi et al. (3) ﬁrst described the use of echocar-
diographic dobutamine stress testing to distinguish
between true severe and pseudosevere AS and noted
that in the absence of ﬂow reserve (i.e., <20% stroke
volume increase with dobutamine infusion), the
TABLE 4 Procedural Characteristics
MT
(n ¼ 44)
SAVR
(n ¼ 52)
TAVR
(n ¼ 108) p Value
Crossover to TAVR 3* (7) 0 (0) NA
Crossover to SAVR 0 (0) NA 1 (1)
General anesthesia NA 52 (100) 43 (40) <0.001
Procedure duration, min NA 190.21  47.73 67.58  38.86 <0.001
Aortic valve intervention
Balloon pre-dilation NA 0 (0) 99 (92) <0.001
Medtronic CoreValve NA 0 (0) 63 (58) <0.001
Edwards SAPIEN valve NA 0 (0) 43 (40) <0.001
Symetis valve NA 0 (0) 2 (2) 1.00
Surgical bioprosthesis NA 52 (100) 1 (1) <0.001
Stentless NA 4 (8) 0 (0) 0.01
Revascularization 7 (16) 36 (69) 39 (36) <0.001
Vessel treated
Left anterior descending artery 6 (14) 30 (58) 26 (24) <0.001
Left circumﬂex artery 3 (7) 24 (46) 7 (7) <0.001
Right coronary artery 1 (2) 24 (46) 12 (11) <0.001
Saphenous vein graft 0 (0) 0 (0) 3 (3) 0.255
Complete revascularization 0 (0) 17 (35) 8 (8) <0.001
Residual SYNTAX score† 20.02  18.59 NA 12.76  14.26 0.019
Percutaneous coronary
intervention
7 (16) 1 (2) 39 (36) <0.001
Concomitant 6 (14) 0 (0) 16 (15) 0.014
Staged 1 (2) 1 (2) 23 (21) <0.001
Coronary artery bypass graft 0 (0) 36 (69) 0 (0) <0.001
Other concomitant interventions 0 (0) 10 (19) 1 (1) <0.001
Carotid endarterectomy NA 1 (10) 0 (0)
Coronary endarterectomy NA 2 (20) 0 (0)
Left atrial appendage occlusion NA 4 (40) 0 (0)
Patent foramen ovale closure NA 1 (10) 1 (100)
Pulmonary vein ablation NA 1 (10) 0 (0)
Subvalvular myectomy NA 1 (10) 0 (0)
Hospital length of stay, days 4.93  5.55 11.94  4.57 8.48  4.13 <0.001
Values are mean  SD with p values from analyses of variance or unpaired Student t tests or n (%) with p values
using the Fisher exact or chi-square test. *Three patients assigned to medical therapy after heart team discussion
subsequently crossed over to TAVR at 833 days (29-mm Medtronic CoreValve), at 25 days (26-mm Edwards
SAPIEN XT valve), and at 493 days (29-mm Medtronic CoreValve) after initial medical therapy allocation.
†Residual SYNTAX score has not been validated in post-CABG patients.
NA ¼ not available; other abbreviations as in Table 1.
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712distinction between true severe and pseudosevere AS
could not be made. Monin et al. (8,9) subsequently
demonstrated that perioperative risk is markedly
increased in LEF-LG severe AS patients without ﬂow
reserve. The same group, however, subsequently
demonstrated that in LEF-LG severe AS patients sur-
viving SAVR, LVEF recovery was independent of
whether ﬂow reserve was present at baseline, sug-
gesting that SAVR should not be contraindicated in
the absence of ﬂow reserve alone (10). Tribouilloy
et al. (13) demonstrated in 42 propensity score–
matched patients that LEF-LG severe AS patients
without ﬂow reserve undergoing SAVR had improved
5-year mortality rates compared with similar patients
undergoing medical management. Although the
perioperative mortality rate was high (22%), theinvestigators concluded that SAVR should not be
withheld from LEF-LG severe AS patients on the basis
of a lack of ﬂow reserve alone (13).
SAVR VERSUS TAVR IN PATIENTS WITH SEVERE AS
AND LOW LVEF. To date, there are only a few studies
comparing TAVR and SAVR treatment modalities in
patients presenting with severe AS and LV systolic
dysfunction (26,27). Furthermore, there is an ongoing
controversy regarding the impact of TAVR versus
SAVR on LV functional recovery in patients present-
ing with severe AS and LV systolic dysfunction
(26,27). Clavel et al. (26) found that TAVR was asso-
ciated with better LVEF recovery compared with
SAVR at 1-year follow-up. Conversely, Elmariah et al.
(27) found no differences in the rate or degree of LV
functional recovery between TAVR and SAVR in pa-
tients with severe AS and an LVEF <50% at baseline.
Both SAVR and TAVR resulted in a similar LVEF
improvement at 1-year follow-up in this post-hoc
analysis of the PARTNER trial (27). The reasons for
this discrepancy may relate to the fact that concom-
itant CABG was not performed in SAVR patients
enrolled in the PARTNER trial, whereas it was per-
formed in 60% of patients in the Clavel et al. study
(26,27). The presence of nonrevascularized CAD at the
initiation of surgery in addition to prolonged cardio-
pulmonary bypass with concomitant CABG were hy-
pothesized to have impeded LVEF recovery in the
SAVR patients in the latter study (26). Both studies,
however, included patients with low LVEF and high
gradients and therefore differ from the present study.
Patients with a low LVEF and high-gradient severe AS
have been shown to have better LVEF recovery and
clinical outcomes compared with those presenting
with a low LVEF and low gradient (5). The present
study compared LVEF recovery exclusively between
low–ejection-fraction, low-gradient severe AS pa-
tients undergoing either TAVR or SAVR. We observed
that LVEF recovery was similar in TAVR and SAVR
patients at 1 year despite the fact that 69% of SAVR
patients underwent concomitant CABG. However,
LVEF recovery occurred earlier among patients un-
dergoing TAVR. These ﬁndings suggest that LVEF re-
covery in LEF-LG severe AS patients undergoing SAVR
may be somewhat delayed due to surgical insults
related to, for example, cardioplegia, ischemia reper-
fusion, apoptosis, and inﬂammation, but that there
then appears to be a “late catch-up” phenomenon.
SAVR VERSUS TAVR IN PATIENTSWITH LOW EJECTION
FRACTION, LOW-GRADIENT SEVERE AS. Herrmann
et al. (18), in a post-hoc analysis of the PARTNER trial,
were the ﬁrst and only group to date to compare
TABLE 5 Unadjusted Clinical Outcomes at 30 Days and 1 Year
Treatment Modality SAVR vs. MT TAVR vs. MT
Overall
p Value
MT
(n ¼ 44)
SAVR
(n ¼ 52)
TAVR
(n ¼ 108) HR or RR (95% CI) p Value HR or RR (95% CI) p Value
30-day follow-up
All-cause death 11 (25.0) 3 (5.8) 6 (5.6) 0.21 (0.06–0.76) 0.017 0.21 (0.08–0.56) 0.002 0.002
Cardiovascular death 10 (23.2) 3 (5.8) 6 (5.6) 0.23 (0.06–0.84) 0.026 0.23 (0.08–0.62) 0.004 0.006
Cerebrovascular events 0 (0.0) 2 (3.8) 6 (5.6) 4.24 (0.21–86.02) 0.50 5.33 (0.31–92.62) 0.18 0.39
Major stroke 0 (0.0) 1 (1.9) 3 (2.8) 2.54 (0.11–60.81) 1.00 2.87 (0.15–54.43) 0.56 0.81
Minor stroke 0 (0.0) 0 (0.0) 1 (0.9) 1.23 (0.05–29.62) 1.00 1.00
Transient ischemic attack 0 (0.0) 1 (1.9) 2 (1.9) 2.54 (0.11–60.81) 1.00 2.05 (0.10–41.85) 1.00 1.00
Myocardial infarction 0 (0.0) 2 (3.8) 1 (0.9) 4.24 (0.21–86.02) 0.50 1.23 (0.05–29.62) 1.00 0.28
All-cause death, major stroke, or MI 11 (25.0) 5 (9.6) 8 (7.4) 0.37 (0.13–1.07) 0.07 0.29 (0.11–0.71) 0.007 0.017
Bleeding 1 (2.3) 5 (9.7) 39 (36.1) 4.21 (0.49–36.03) 0.19 17.79 (2.44–129.57) 0.004 <0.001
Life-threatening 0 (0.0) 2 (3.8) 14 (13.0) 4.24 (0.21–86.02) 0.50 11.89 (0.72–195.04) 0.011 0.009
Major 1 (2.3) 3 (5.9) 14 (13.1) 2.46 (0.26–23.69) 0.44 5.90 (0.78–44.88) 0.09 0.11
Minor 0 (0.0) 0 (0.0) 14 (13.1) 11.89 (0.72–195.04) 0.011 0.001
Acute renal failure 5 (11.6) 17 (32.7) 17 (16.2) 3.07 (1.13–8.32) 0.028 1.49 (0.55–4.03) 0.44 0.031
Vascular complications 0 (0.0) 2 (3.8) 19 (17.7) 4.24 (0.21–86.02) 0.50 16.00 (0.99–259.29) 0.002 0.001
Major 0 (0.0) 2 (3.8) 8 (7.5) 4.24 (0.21–86.02) 0.50 6.97 (0.41–118.20) 0.11 0.15
Minor 0 (0.0) 0 (0.0) 11 (10.2) 9.43 (0.57–156.61) 0.034 0.005
Repeat unplanned intervention 1 (2.3) 2 (3.8) 1 (0.9) 1.71 (0.15–18.83) 0.66 0.41 (0.03–6.57) 0.53 0.51
Permanent pacemaker implantation 1 (2.3) 1 (2.0) 27 (25.6) 0.80 (0.05–12.85) 0.88 11.98 (1.63–88.19) 0.015 0.002
1-year follow-up
All-cause death 26 (59.2) 7 (13.9) 27 (25.1) 0.16 (0.07–0.38) <0.001 0.30 (0.18–0.52) <0.001 <0.001
Cardiovascular death 25 (58.2) 5 (9.6) 24 (22.6) 0.12 (0.05–0.32) <0.001 0.29 (0.16–0.50) <0.001 <0.001
Cerebrovascular events 0 (0.0) 2 (3.8) 7 (6.6) 4.24 (0.21–86.02) 0.50 6.15 (0.36–105.41) 0.19 0.25
Major stroke 0 (0.0) 1 (1.9) 4 (3.8) 2.54 (0.11–60.81) 1.0 3.69 (0.20–67.12) 0.32 0.61
Minor stroke 0 (0.0) 0 (0.0) 1 (0.9) 1.23 (0.05–29.62) 1.0 1.00
Transient ischemic attack 0 (0.0) 1 (1.9) 2 (1.9) 2.54 (0.11–60.81) 1.0 2.05 (0.10–41.85) 1.0 1.00
MI 0 (0.0) 3 (6.1) 1 (0.9) 5.93 (0.31–111.74) 0.25 1.23 (0.05–29.62) 1.0 0.10
All cause death, major stroke, or MI 26 (59.2) 9 (17.5) 30 (27.9) 0.23 (0.11–0.48) <0.001 0.36 (0.21–0.60) <0.001 <0.001
Values are number of events (incidence rates from life tables %). HR (95% CI) from Cox regressions. In case of zero events, continuity corrected RR (95% CI) and Fisher exact
test p values are reported.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; RR ¼ relative risk.
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713clinical outcomes of patients with low ejection frac-
tion (<50%), low-gradient (<40 mm Hg) severe
AS (AVA <0.8 cm2 or indexed AVA <0.5 cm2$m2)
according to treatment modality. The investigatorsTABLE 6 Adjusted Clinical Outcomes at 30 Days and 1 Year
Treatment Modality
MT
(n ¼ 44)
SAVR
(n ¼ 52)
TAVR
(n ¼ 108)
30-day follow-up
All-cause death 11 (25.0) 3 (5.8) 6 (5.6)
Cardiovascular death 10 (23.2) 3 (5.8) 6 (5.6)
All-cause death, major stroke, or MI 11 (25.0) 5 (9.6) 8 (7.4)
1-year follow-up
All cause death 26 (59.2) 7 (13.9) 27 (25.1)
Cardiovascular death 25 (58.2) 5 (9.6) 24 (22.6)
All-cause death, major stroke, or MI 26 (59.2) 9 (17.5) 30 (27.9)
Values are number of events (incidence rates from life tables %). Adjusted HR (95% C
terolemia, peripheral vascular disease, SYNTAX score, previous cardiac surgery, atrial ﬁbr
chained equations (20 datasets produced).
Abbreviations as in Tables 1 and 5.found that TAVR improved 2-year survival compared
with MT (PARTNER B cohort) and revealed for the
ﬁrst time that LEF-LG severe AS patients undergoing
TAVR and SAVR had similar clinical outcomes at 2SAVR vs. MT TAVR vs. MT
Overall
p ValueHR (95% CI) p Value HR (95% CI) p Value
0.64 (0.16–2.61) 0.54 0.36 (0.13–1.04) 0.058 0.17
0.72 (0.17–2.99) 0.65 0.39 (0.13–1.13) 0.08 0.22
1.02 (0.31–3.35) 0.97 0.47 (0.18–1.21) 0.12 0.23
0.37 (0.15–0.93) 0.034 0.43 (0.24–0.79) 0.006 0.011
0.30 (0.11–0.84) 0.023 0.41 (0.22–0.76) 0.004 0.006
0.53 (0.23–1.22) 0.13 0.53 (0.30–0.93) 0.028 0.07
I) from Cox regressions, adjusting for the following baseline variables: hypercholes-
illation, and the logistic EuroSCORE after multiple imputations of missing values using
FIGURE 2 Kaplan-Meier Curves for Clinical Outcomes According to Assigned Treatment Modality
Kaplan-Meier analysis of death (A) and cardiovascular death (B) at 1 year according to the assigned treatment modality. Abbreviations
as in Figure 1.
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714years (PARTNER A cohort) (18). However, this study
was limited by the fact that the PARTNER trial sys-
tematically excluded all patients with CAD requiring
revascularization and an LVEF <20%, and no follow-
up echocardiography was reported (18). However,
previous studies have shown that 66% to 69% of LEF-
LG severe AS patients have concomitant CAD, and
60% to 62% of LEF-LG severe AS patients undergoing
SAVR also undergo concomitant CABG (4,6). The
present study provides “real-world” clinical out-
comes of LEF-LG severe AS patients undergoingFIGURE 3 Kaplan-Meier Curves for Clinical Outcomes Stratiﬁed by S
Kaplan-Meier analysis of death (A) and cardiovascular death (B) at 1 ye
patients with low-ﬂow, low-gradient severe aortic stenosis undergoing ei
from this analysis. CAD ¼ coronary artery disease; other abbreviations arevascularization procedures according to the
assigned treatment modality. We conﬁrmed that LEF-
LG severe AS patients undergoing MT have a dismal
outcome and also observed that LEF-LG severe AS
patients assigned to TAVR and SAVR had similar
outcomes at 30 days and 1 year despite the fact that
SAVR patients were at signiﬁcantly lower operative
risk at baseline. CAD was present in almost three-
fourths of LEF-LG severe AS patients included in the
present study. However, LEF-LG severe AS patients
undergoing SAVR were more likely to undergoYNTAX Score Among TAVR and SAVR Patients Only
ar according to CAD severity as assessed using the SYNTAX score in
ther conventional SAVR or TAVR. Patients receiving MT were excluded
s in Figure 1.
FIGURE 4 Kaplan-Meier Curves for Clinical Outcomes Stratiﬁed by Completeness of Revascularization Among TAVR and SAVR Patients Only
Kaplan-Meier analysis of death (A) and cardiovascular death (B) at 1 year according to the completeness of revascularization among patients
with low-ﬂow, low-gradient severe aortic stenosis undergoing either conventional SAVR or TAVR. Patients receiving MT were excluded from
this analysis. Revasc ¼ revascularization; other abbreviations as in Figures 1 and 3.
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715revascularization procedures compared with patients
undergoing TAVR despite a similar degree of CAD
complexity at baseline. In addition, a SS higher than
22 was an independent predictor of cardiovascularTABLE 7 Post-Procedural Changes in Echocardiographic Parameters
SAVR
(n ¼ 52)
TAVR
(n ¼ 108) p Value
AVA, cm2
Baseline 0.73  0.23 0.74  0.21 0.88
Discharge 1.89  0.43 1.80  0.60 0.62
1 year 1.68  0.53 1.76  0.49 0.66
Indexed AVA, cm2$m2
Baseline 0.41  0.12 0.42  0.12 0.57
Discharge 1.03  0.22 1.05  0.37 0.90
1 year 0.94  0.27 1.00  0.27 0.49
Mean gradient, mm Hg
Baseline 29.3  9.5 28.6  10.3 0.69
Discharge 9.5  3.4 7.2  2.9 0.001
1 year 11.5  3.6 8.1  2.9 <0.001
Peak gradient, mm Hg
Baseline 48.3  15.9 46.6  16.0 0.53
Discharge 16.9  6.9 12.9  4.9 0.002
1 year 21.0  6.2 15.3  5.6 0.001
LV ejection fraction, %
Baseline 38.9  12.0 34.5  11.4 0.029
Discharge 38.8  12.6 39.0  12.4 0.92
1 year 46.6  13.2 46.1  12.8 0.88
PASP, mm Hg
Baseline 45.5  11.9 52.0  13.9 0.016
Discharge 36.2  10.9 46.9  13.9 0.001
1 year 39.6  15.3 42.0  11.8 0.54
Values are mean  SD.
AVA ¼ aortic valve area; PASP ¼ pulmonary artery systolic pressure; other
abbreviations as in Tables 1 and 2.death at 1 year in LEF-LG severe AS patients under-
going either TAVR or SAVR. Furthermore, incomplete
revascularization was an independent predictor of
cardiovascular mortality in LEF-LG severe AS patients
undergoing TAVR and SAVR. This suggests that
revascularization strategies are an important compo-
nent of the overall management of LEF-LG severe AS
patients, particularly in patients with high CAD
complexity. Recently, Stefanini et al. (21) found that
in an unselected patient population with severe
AS undergoing TAVR only, those with a residual SS
higher than 14 had a worse clinical outcome at 1 year.
Hence, complete revascularization should be the goalFIGURE 5 Left Ventricular Ejection Fraction Recovery
Over Time
Changes in LVEF over time in patients with low-ﬂow, low-
gradient severe aortic stenosis undergoing either conventional
SAVR or TAVR. ns ¼ nonsigniﬁcant; other abbreviations as in
Figure 1.
PERSPECTIVES
WHAT IS KNOWN: Patients with low ejection frac-
tion, low-gradient (LEF-LG) severe aortic stenosis
(AS) undergoing conventional surgical aortic valve
replacement (SAVR) typically have a high prevalence
of concomitant coronary artery disease (CAD) and a
poor prognosis.
WHAT IS NEW: A higher SYNTAX score at baseline is
associated with signiﬁcantly higher rates of 1-year
cardiovascular mortality among LEF-LG severe AS
patients undergoing SAVR and TAVR. LEF-LG severe
AS patients undergoing TAVR and SAVR with incom-
plete revascularization and concomitant CAD have
signiﬁcantly higher cardiovascular mortality rates at
1 year compared with similar patients with no CAD or
complete revascularization.
WHAT IS NEXT: Further clinical trials are needed to
develop an optimized interventional or surgical
strategy for patients with symptomatic LEF-LG severe
AS. Reﬁned medical and electrophysiological post-
interventional treatment strategies may help reduce
the risk of cardiovascular mortality.
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CAD, and this target may be better achieved with
SAVR and CABG in operable LEF-LG severe AS pa-
tients with concomitant CAD of high complexity.
STUDY LIMITATIONS. There are several limitations
that need to be considered when interpreting the
present study. First, this was a single-center, obser-
vational study, and therefore our results may contain
unmeasured bias. Second, propensity score matching
and inverse probability treated weighting were not
performed due to the relatively low numbers of pa-
tients in each group, and the results should therefore
be considered mainly descriptive. However, all clin-
ical outcomes were adjusted for signiﬁcant univari-
ate predictors of the primary endpoint, and the
number of LEF-LG severe AS patients compares
favorably with that of the PARTNER substudy (18).
Third, the residual SS after CABG has never been
validated, and therefore we were unable to deter-
mine in the present study whether a certain
threshold of residual CAD exists that may be asso-
ciated with worse clinical outcomes at 1 year. Finally,
dobutamine stress echocardiography was performed
in only one-fourth of patients, and we were therefore
unable to compare the impact of a lack of ﬂow
reserve on clinical outcomes according to treatment
modality.
CONCLUSIONS
Both TAVR and SAVR improved survival compared
with MT in LEF-LG severe AS patients, whereas clin-
ical outcomes of TAVR and SAVR appeared similar
among appropriately selected patients with LEF-LG
severe AS at 1-year follow-up. Concomitant CAD is
highly prevalent among LEF-LG severe AS patients
and a baseline SS higher than 22 was an independent
predictor of cardiovascular death at 1 year among
LEF-LG severe AS patients undergoing either TAVR orSAVR. Furthermore, LEF-LG severe AS patients with
concomitant CAD who underwent incomplete revas-
cularization had worse outcomes at 1 year. Therefore,
revascularization strategies are an important compo-
nent of the overall management of LEF-LG severe AS
patients undergoing either TAVR or SAVR.
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